Sp1299
UNDERSTANDING ZYMFENTRA: THE FIRST AND ONLY SUBCUTANEOUS INFLIXIMAB OFFERING A NEW THERAPEUTIC APPROACH IN CD AND UC MAINTENANCE
Date
May 21, 2024
Presenter
Northwestern Feinberg School of Medicine
Tracks
Related Products
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
AGA Farron and Martin Brotman, MD, Lecture — Transforming IBD Care 1: The Biologic Revolution — Past, Present and Future
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
BOWEL URGENCY IN ULCERATIVE COLITIS
SOCIETY: DDW
